RxDoctor Payments Data

Alan Antfleck, MD

Internal Medicine · Kenmore, NYNPI 1154365559

Payments from drug & device makers

$20,451in general payments, 2019–2025

Across 500 payments — averaging $40.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • Amgen$2K
  • AbbVie$1K
  • Sanofi-aventis U.S. LLC$1K
  • Boehringer Ingelheim$1K
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$20,427100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca50$3,145
Novo Nordisk74$2,307
Amgen55$1,797
AbbVie(2 entities)49$1,417
Sanofi-aventis U.S. LLC11$1,115
Boehringer Ingelheim9$1,077
Phathom Pharmaceuticals, Inc.7$836
Johnson & Johnson13$752
Lilly USA, LLC25$704
Pfizer30$608
Teva Pharmaceuticals USA, Inc.8$555
Biohaven Pharmaceuticals, Inc.8$505
Esperion Therapeutics, Inc.6$407
Paratek Pharmaceuticals, Inc.4$394
Amarin Pharma, Inc.21$342
Gilead3$325
Bayer3$274
Radius Health, Inc.9$259
Merck5$257
E.r. Squibb & Sons, L.L.C.2$250
Boston Scientific2$238
Exact Sciences4$184
Biohaven Pharmaceutical Holding Company Ltd.4$164
Astellas Pharma US Inc10$157
Takeda Pharmaceuticals U.S.A., Inc.20$151
Cvrx, Inc.1$145
Urovant Sciences Inc4$132
Ironwood Pharmaceuticals, Inc1$125
Mannkind Corporation1$125
Lundbeck LLC1$125
Avanir Pharmaceuticals, Inc.1$125
GSK1$121
Impel Pharmaceuticals Inc.1$115
Idorsia Pharmaceuticals US Inc6$111
SK Life Science, Inc.1$106
Sumitomo Pharma America, Inc.6$105
Corcept Therapeutics1$100
Neurocrine Biosciences, Inc.1$97
Therapeuticsmd, Inc.5$83
Eisai Inc.4$57
Organon3$52
Exeltis, USA Inc.3$50
Vertical Pharmaceuticals, LLC3$50
Mylan Pharmaceuticals Inc.3$48
Daiichi Sankyo Inc.3$44
Zyla Life Sciences, Inc.2$37
Upsher-smith Laboratories LLC1$26
Lupin Inc.2$26
Kowa Pharmaceuticals America, Inc.1$25
Hologic Sales And Service, LLC1$24
Ascend Therapeutics US, LLC1$22
Shield Therapeutics Inc1$22
Virtus Pharmaceuticals LLC1$20
Mayne Pharma Commercial LLC1$18
Roche Diagnostics Corporation1$17
Covis Pharma GmbH1$16
Medtronic1$16
AMAG Pharmaceuticals, Inc.1$15
Alfasigma USA, Inc.1$15
Novartis1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,451 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$6,756
Medicare patients
23
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$53,549
OzempicSemaglutide24$44,778
EliquisApixaban23$13,690
RybelsusSemaglutide14$12,673
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,834
TrintellixVortioxetine Hydrobromide12$6,033
Atorvastatin Calcium174$2,701
SynthroidLevothyroxine Sodium28$2,280
Rosuvastatin Calcium100$1,631
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$1,568
Ezetimibe77$1,526
Levothyroxine Sodium89$1,410
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide26$1,251
Gabapentin41$978
Amlodipine Besylate107$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,307$57,45138 claims
Boehringer IngelheimJardiance$1,077$53,54939 claims
PfizerEliquis$608$13,69023 claims
AstraZenecaBreztri Aerosphere$3,145$8,83412 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$151$6,03312 claims
AbbVieSynthroid$1,417$2,28028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Kenmore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →